 John. R. Edwardson on Aug 17th, 2018 // No Comments
DexCom, Inc. (NASDAQ:DXCM) VP Patrick Michael Murphy sold 12,500 shares of DexCom stock in a transaction on Friday, August 10th. The shares were sold at an average price of $124.18, for a total value of $1,552,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website .
NASDAQ DXCM opened at $128.31 on Friday. The stock has a market capitalization of $10.90 billion, a P/E ratio of -221.22 and a beta of 0.05. The company has a quick ratio of 4.62, a current ratio of 4.89 and a debt-to-equity ratio of 0.69. DexCom, Inc. has a 12 month low of $42.62 and a 12 month high of $129.09. Get DexCom alerts:
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.08. The business had revenue of $242.50 million during the quarter, compared to the consensus estimate of $205.81 million. DexCom had a negative return on equity of 7.45% and a negative net margin of 0.65%. The firm's revenue was up 42.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.16) earnings per share. equities research analysts predict that DexCom, Inc. will post -0.48 EPS for the current year. Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Signaturefd LLC bought a new stake in DexCom in the first quarter valued at about $105,000. Cerebellum GP LLC bought a new stake in DexCom in the second quarter valued at about $171,000. SG Americas Securities LLC bought a new stake in DexCom in the first quarter valued at about $175,000. Clinton Group Inc. acquired a new position in DexCom in the second quarter valued at about $201,000. Finally, Bank Pictet & Cie Asia Ltd. acquired a new position in DexCom in the second quarter valued at about $218,000.
DXCM has been the subject of several research analyst reports. Canaccord Genuity lifted their price objective on DexCom from $85.00 to $105.00 and gave the company a "buy" rating in a research report on Thursday, June 28th. ValuEngine upgraded DexCom from a "hold" rating to a "buy" rating in a research report on Thursday, May 3rd. Bank of America started coverage on DexCom in a research report on Friday, May 11th. They set a "buy" rating and a $100.00 target price for the company. BidaskClub downgraded DexCom from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, July 31st. Finally, Oppenheimer set a $125.00 target price on DexCom and gave the stock a "buy" rating in a research report on Thursday, August 2nd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of "Buy" and an average target price of $103.19.
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system